Table of Contents_x000D_
List of Tables_x000D_
List of Figures_x000D_
1 Introduction_x000D_
1.1 What Is This Report About?_x000D_
1.2 Hematological Disorders Market Segmentation_x000D_
1.3 Definitions of Markets Covered in the Report_x000D_
2 Hematological Disorders Market, United States_x000D_
2.1 Hematological Disorders Market, United States, Revenue ($m), 2024-2036_x000D_
2.1.1 Hematology Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_
2.1.2 Hemostasis Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_
2.2 Hematological Disorders Market, United States, Volume (Units), 2024-2036_x000D_
2.2.1 Hematology Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_
2.2.2 Hemostasis Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_
2.3 Hematological Disorders Market, United States, Average Price ($), 2024-2036_x000D_
2.4 Hematological Disorders Market, United States, Company Share by Revenue ($m), 2025_x000D_
3 Hematological Disorders Market Pipeline Products_x000D_
3.1 Hematological Disorders Market Pipeline Products_x000D_
3.2 Hematological Disorders – Pipeline Products by Stage of Development_x000D_
3.3 Hematological Disorders – Pipeline Products by Segment_x000D_
3.4 Hematological Disorders – Pipeline Products by Territory_x000D_
3.5 Hematological Disorders – Pipeline Products by Regulatory Path_x000D_
3.6 Hematological Disorders – Pipeline Products by Estimated Approval Date_x000D_
4 Overview of Key Companies in United States, Hematological Disorders Market_x000D_
4.1 Abbott Laboratories_x000D_
4.1.1 Company Overview_x000D_
4.2 Roche Diagnostics International Ltd_x000D_
4.2.1 Company Overview_x000D_
4.3 Sysmex Corp_x000D_
4.3.1 Company Overview_x000D_
4.4 Siemens AG_x000D_
4.4.1 Company Overview_x000D_
4.5 Instrumentation Laboratory Co_x000D_
4.5.1 Company Overview_x000D_
4.6 Diagnostica Stago SAS_x000D_
4.6.1 Company Overview_x000D_
4.7 Beckman Coulter Inc_x000D_
4.7.1 Company Overview_x000D_
4.8 Quidel Corp_x000D_
4.8.1 Company Overview_x000D_
4.9 Radiometer Medical ApS_x000D_
4.9.1 Company Overview_x000D_
4.10 Thermo Fisher Scientific Inc_x000D_
4.10.1 Company Overview_x000D_
5 Recent Developments_x000D_
5.1 Corporate Communications_x000D_
5.1.1 May 18, 2026: Texas Children’s Faculty Receive More Than $5.6M in Research Grants_x000D_
5.1.2 Nov 20, 2025: Quanterix Announces Board and Leadership Changes_x000D_
5.1.3 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors_x000D_
5.1.4 Nov 12, 2025: Pillar Biosciences Launches New NGS Panel for Tumor Profiling of Lymphoid Malignancies_x000D_
5.1.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
5.1.6 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth_x000D_
5.1.7 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager_x000D_
5.1.8 Oct 29, 2025: Regenerative Medicine Also Known As Stem Cell Therapy_x000D_
5.1.9 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder_x000D_
5.1.10 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch_x000D_
5.1.11 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.1.12 Oct 08, 2025: Virogates A/S Announces Public Tender Offer to Shareholders_x000D_
5.1.13 Oct 01, 2025: Predicta Biosciences Raises $23.4M to Expand Diagnostic Platform for Blood Cancers_x000D_
5.1.14 Oct 01, 2025: Castle Biosciences’ Derek Maetzold Named CEO of the Year by The CEO Magazine_x000D_
5.1.15 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions_x000D_
5.1.16 Sep 15, 2025: Mdxhealth Completes Acquisition of Exosome Diagnostics from Bio-Techne_x000D_
5.2 Government and Public Interest_x000D_
5.2.1 Nov 24, 2025: Adaptive Biotechnologies to Present Nearly 90 Abstracts Featuring clonoSEQ MRD Testing at 67th ASH Meeting_x000D_
5.2.2 Nov 13, 2025: Telo Genomics to Present Individual-Cell Risk Assessment MRD Technology at Myeloma Canada Summit_x000D_
5.3 Other Significant Developments_x000D_
5.3.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months_x000D_
5.3.2 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors_x000D_
5.3.3 Nov 05, 2025: YD Bio and EG BioMed Expand U.S. Access to OkaiDx for Breast Cancer Monitoring_x000D_
5.3.4 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth_x000D_
5.3.5 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab_x000D_
5.3.6 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch_x000D_
5.3.7 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.3.8 Oct 08, 2025: Virogates A/S Announces Public Tender Offer to Shareholders_x000D_
5.3.9 Sep 19, 2025: NDSU Annual Research Awards Total $93.5 Million_x000D_
5.4 Product News_x000D_
5.4.1 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV_x000D_
5.4.2 Nov 24, 2025: Adaptive Biotechnologies to Present Nearly 90 Abstracts Featuring clonoSEQ MRD Testing at 67th ASH Meeting_x000D_
5.4.3 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months_x000D_
5.4.4 Nov 13, 2025: Telo Genomics to Present Individual-Cell Risk Assessment MRD Technology at Myeloma Canada Summit_x000D_
5.4.5 Nov 13, 2025: Single Digit Parts Per Million Detection of Molecular Residual Disease Through Integrated Tumor-Informed Whole-Genome Sequencing Analysis_x000D_
5.4.6 Nov 05, 2025: YD Bio and EG BioMed Expand U.S. Access to OkaiDx for Breast Cancer Monitoring_x000D_
5.4.7 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab_x000D_
5.4.8 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder_x000D_
5.4.9 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch_x000D_
5.4.10 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.4.11 Oct 09, 2025: American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at 2025 Meeting_x000D_
5.4.12 Oct 02, 2025: Hologic Receives FDA Clearance And CE Mark For Automated Molecular Tests To Detect Infectious Gastroenteritis_x000D_
5.4.13 Oct 01, 2025: Predicta Biosciences Raises $23.4M to Expand Diagnostic Platform for Blood Cancers_x000D_
5.5 Research And Development_x000D_
5.5.1 Feb 04, 2026: Advancing Early Detection for Kidney Disease in Sickle Cell_x000D_
5.6 Strategy And Business Planning_x000D_
5.6.1 Mar 13, 2026: University Hospitals to Build Modern Pathology Laboratory_x000D_
5.6.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
5.6.3 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics_x000D_
5.6.4 Oct 14, 2025: START, Together With HM Hospitales, Inaugurates Spain’s First Pediatric Onco-Hematology Clinical Research Unit_x000D_
5.6.5 Oct 02, 2025: AIxMed And Biopticka Laborator Announce Strategic Collaboration On AI-Cytology In Europe_x000D_
5.6.6 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions_x000D_
6 Appendix_x000D_
6.1 Research Methodology_x000D_
6.1.1 Coverage_x000D_
6.1.2 Secondary Research_x000D_
6.1.3 Primary Research_x000D_
6.1.4 Market Modeling and Forecasting_x000D_
6.1.5 Company Share Analysis_x000D_
6.1.6 Benchmarking_x000D_
6.2 GlobalData Consulting_x000D_
6.3 Contact Us_x000D_
6.4 Disclaimer